Using special nanorings to direct immune cells to kill cancer cells
Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)
This study is exploring a new way to boost cancer treatment by using tiny rings that can help your immune system, especially T-cells, better fight cancer cells, aiming to make treatment more effective and easier for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10786101 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to enhance cancer immunotherapy by using chemically self-assembled nanorings (CSANs) that can target and activate immune cells, specifically T-cells, to attack cancer cells. The approach involves creating stable nanorings that can be easily modified to carry various therapeutic agents, allowing for a more effective and targeted treatment. By utilizing these nanorings, the research aims to overcome some limitations of current therapies, such as the need for continuous infusion and the risk of cancer cells evading treatment. Patients may benefit from a more efficient and potentially less invasive cancer treatment option.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancers that express target antigens suitable for CSAN therapy.
Not a fit: Patients with cancers that do not express the target antigens or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments that improve patient outcomes.
How similar studies have performed: While the use of nanotechnology in cancer treatment is a growing field, this specific approach using CSANs is novel and has not been extensively tested in clinical settings.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Wagner, Carston R. — University of Minnesota
- Study coordinator: Wagner, Carston R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.